From opioid research to plastics recycling, here are three research projects to watch out for in Houston. Photo via Getty Images

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research projects, we look into studies on robotics advancing stroke patient rehabilitation, the future of opioid-free surgery, and a breakthrough in recycling plastics.

The University of Houston's research on enhancing stroke rehabilitation

A clinical trial from a team at UH found that stroke survivors gained clinically significant arm movement and control by using an external robotic device powered by the patients' own brains. Image via UH.edu

A researcher at the University of Houston has seen positive results on using his robotics on stroke survivors for rehabilitation. Jose Luis Contreras-Vidal, director of UH's Non-Invasive Brain Machine Interface Systems Laboratory, recently published the results of the clinical trial in the journal NeuroImage: Clinical.

The testing proved that most patients retained the benefits for at least two months after the therapy sessions ended, according to a press release from UH, and suggested even more potential in the long term. The study equipped stroke survivors who have limited movement in one arm with a computer program that captures brain activity to determine the subject's intentions and then works with a robotic device affixed to the affected arm, to move in response to those intentions.

"This is a novel way to measure what is going on in the brain in response to therapeutic intervention," says Dr. Gerard Francisco, professor and chair of physical medicine and rehabilitation at McGovern Medical School at The University of Texas Health Science Center at Houston and co-principal investigator, in the release.

"This study suggested that certain types of intervention, in this case using the upper robot, can trigger certain parts of brain to develop the intention to move," he continues. "In the future, this means we can augment existing therapy programs by paying more attention to the importance of engaging certain parts of the brain that can magnify the response to therapy."

The trial was funded by the National Institute of Neurological Disorders and Stroke and Mission Connect, part of the TIRR Foundation. Contreras-Vidal is working on a longer term project with a National Science Foundation grant in order to design a low-cost system that would allow people to continue the treatments at home.

"If we are able to send them home with a device, they can use it for life," he says in the release.

Baylor College of Medicine's work toward opioid-free surgery

A local doctor is focused on opioid-free options. Photo via Getty Images

In light of a national opioid crisis and more and more data demonstrating the negative effects of the drugs, a Baylor College of Medicine orthopedic surgeon has been working to offer opioid-free surgery recovery to his patients.

"Thanks to a number of refinements, we are now able to perform hip and knee replacements, ranging from straightforward to very complex cases, without patients requiring a single opioid pill," says Dr. Mohamad Halawi, associate professor and chief quality officer in the Joseph Barnhart Department of Orthopedic Surgery, in a press release.

"Pain is one of patients' greatest fears when undergoing surgery, understandably so," Halawi continues. "Today, most patients wake up from surgery very comfortable. Gone are the days of trying to catch up with severe pain. It was a vicious cycle with patients paying the price in terms of longer hospitalization, slower recovery and myriad adverse events."

Halawi explains that his work focuses on preventative measures ahead of pain occurring as well as cutting out opioids before surgery.

"Opioid-free surgery is the way of the future, and it has become a standard of care in my practice," he says. "The ability to provide safer and faster recovery to all patients regardless of their surgical complexity is gratifying. I want to make sure that pain is one less thing for patients to worry about during their recovery."

Rice University's breakthrough on recycling plastics

A team of scientists have found a use for a material that comes out of plastics recycling. Photo via Rice.edu

Houston scientists has found a new use for an otherwise useless byproduct that comes from recycling plastics. Rice University chemist James Tour has discovered that turbostratic graphene flakes can be produced from pyrolyzed plastic ash, and those flakes can then be added to other substances like films of polyvinyl alcohol that better resist water in packaging and cement paste and concrete, as well as strengthen the material.

"This work enhances the circular economy for plastics," Tour says in a press release. "So much plastic waste is subject to pyrolysis in an effort to convert it back to monomers and oils. The monomers are used in repolymerization to make new plastics, and the oils are used in a variety of other applications. But there is always a remaining 10% to 20% ash that's valueless and is generally sent to landfills.

Tour's research has appeared in the journal Carbon. The co-authors of the study include Rice graduate students Jacob Beckham, Weiyin Chen and Prabhas Hundi and postdoctoral researcher Duy Xuan Luong, and Shivaranjan Raghuraman and Rouzbeh Shahsavari of C-Crete Technologies. The National Science Foundation, the Air Force Office of Scientific Research and the Department of Energy supported the research.

"Recyclers do not turn large profits due to cheap oil prices, so only about 15% of all plastic gets recycled," said Rice graduate student Kevin Wyss, lead author of the study. "I wanted to combat both of these problems."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.